As of September 18, 2026, PFIZER's technical stance is characterized by a bearish trend across daily, weekly, and monthly timeframes, with the current price of ₹4002.4 trading below key moving averages and the Supertrend indicator on all observed periods. This indicates a lack of upward momentum and suggests overhead pressure. The stock has recently formed an Outside Bar pattern on the daily chart, which can sometimes signal a potential shift in sentiment, though its immediate impact is unclear given the prevailing bearish conditions.

Nearest support is observed around ₹3986.87, approximately 0.39% below the current price, with further support at ₹3982.0. Resistance is noted at ₹4013.43, just 0.28% above the current price, followed by ₹4041.37. The stock's risk profile includes an annualized volatility of 26% and a current drawdown of -32%, highlighting the potential for significant price swings.

Key conditions to monitor include the price's ability to move above the nearest resistance level at ₹4013.43 and sustain the move. Conversely, a break below the support level at ₹3986.87 could signal further downside. The recent anomaly on September 11, 2026, which showed high participation with no clear direction, and the downward gap on September 8, 2026, warrant attention for any potential follow-through.

Pfizer Limited's 75th Annual General Meeting (AGM) was held on July 28, 2026, where shareholders approved all proposed resolutions. These included the adoption of financial statements for the year ending March 31, 2026, and the declaration of a final dividend of ₹75 per equity share. The company also announced its unaudited financial results for the quarter ended June 30, 2026, reporting a total income of ₹698.01 crore and a net profit of ₹204.47 crore. These results were subject to a limited review by statutory auditors. Additionally, a special window for re-lodgement of transfer and dematerialisation of physical securities was announced, running from February 5, 2026, to February 4, 2027, for specific types of securities. A board meeting outcome was also noted on September 7, 2026, though the summary details were not provided in the evidence.

As of September 18, 2026, Pfizer's stock price has seen a slight decrease, closing at ₹4002.4 compared to its previous price of ₹4014.8. The available evidence does not indicate any new filings or news developments for the company. The company continues to be listed on the NSE.

Pfizer Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, reporting a total income of ₹698.01 crore and a net profit of ₹204.47 crore. These results were subject to a limited review by statutory auditors, B S R & Co. LLP, with no modifications noted. The company also announced a final dividend of ₹75 per equity share, which was approved at the 75th Annual General Meeting held on July 28, 2026. In a management change, Mr. Amit Agarwal resigned as Executive Director – Finance & Chief Financial Officer, effective October 8, 2026. Additionally, the company is offering a special window for the re-lodgement of transfer and dematerialisation of physical securities from February 5, 2026, to February 4, 2027, for specific transactions.

Pfizer's reported results show a generally positive operating trajectory. Revenue from operations has seen an increase from ₹645.03 crore in Q3 FY2025-26 to ₹653.17 crore in Q1 FY2026-27. This top-line growth has been accompanied by an improvement in profitability. Profit Before Exceptional Items And Tax rose from ₹250.15 crore in Q3 FY2025-26 to ₹276.68 crore in Q1 FY2026-27. The company's net profit, Profit Loss For Period, also followed this upward trend, increasing from ₹141.84 crore in Q3 FY2025-26 to ₹204.47 crore in Q1 FY2026-27. While expenses have also risen, the growth in revenue appears to be outpacing expense increases, contributing to improved profit margins. Finance costs have remained relatively low and stable across the reported periods.

Key monitoring areas for Pfizer would include the sustainability of revenue growth and the continued management of expenses to maintain or improve profit margins. Investors may also wish to track any significant changes in exceptional items or tax provisions that could impact the final profit for the period.

As of September 18, 2026, Pfizer's stock is trading at ₹4002.4. While the daily and monthly technical trends indicate a bearish sentiment with Supertrend values above the closing price (₹4319.89 daily, ₹6078.81 monthly), and moving averages like the 20-day EMA (₹4369.06) and 50-day EMA (₹4556.14) are also above the current price, suggesting downward momentum, the stock is currently positioned near several support levels. The nearest support is at ₹3986.87, which is approximately 0.39% below the current price. The company has experienced a drawdown of -32%, with a maximum drawdown also at -32%, indicating the extent of its recent price decline.

The company's stock is exhibiting a bearish trend across multiple timeframes, with its current price trading below key moving averages. Technical indicators suggest a lack of strong upward momentum, and the stock has experienced significant drawdowns. This technical setup, coupled with negative returns over various periods, indicates potential headwinds.